Effect of sacubitril/valsartan on serum potassium levels in auric patients on hemodialysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074610

Enrollment

Unknown

Registered

2023-08-10

Start date

2023-08-20

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease

Interventions

Case series group:None

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Undergo 3-4 times weekly hemodialysis treatment for at least 3 months; 2. Age 18-85 years old; 3. Urine output <100 ml in 24 hours; 4. Received a total course of treatment with sacubitril/valsartan for more than 3 months.

Exclusion criteria

Exclusion criteria: Stroke or myocardial infarction within the previous 3 months; active malignancy, or cachexia.

Design outcomes

Primary

Measure	Time frame
Mean serum potassium ;Peak serum potassium;	—

Secondary

Measure	Time frame
Blood pressure;Serum sodium;Body weight;Serum bicarbonate;Kt/V;	—

Countries

China

Contacts

Public ContactXiaofanLi

Peking University Shougang Hospital

lixiaofan0626@163.com+86 134 2618 0175

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026